GSK forecasts slower sales growth in 2026
Feb 4 (Reuters) - GSK on Wednesday forecast sales growth to slow in 2026 in the first outlook presented by new CEO Luke Miels as the drugmaker shifts focus on expanding its pipeline to counter looming patent expiries for its top-selling HIV drugs.
The firm expects revenue to grow 3 % to 5% this year, at constant currency rates, after rising 7% in 2025.
(Reporting by Sri Hari N S, Pushkala Aripaka in Bengaluru, and Bhanvi Satija in London; Editing by Sonia Cheema)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Raytheon Shares Rise 4.5% as Middle East Unrest Grows: Key Information for Investors
Gold price to accelerate and hit new record highs after this event – technical analyst
Gold price to accelerate and hit new record highs after this event – technical analyst
Pundit Predicts 1000 x $1.35 By the End of This Cycle. Here’s why
Trending news
MoreCrypto prices
More
